Related Experiment Videos
[Amotivational syndrome in organic solvent abusers]
1Division of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, 1-7-3 Kohnodai, Ichikawa-shi, Chiba-ken 272-0827, Japan. ozaki@ncnp-k.go.jp
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|March 10, 2001
Summary
Amotivational syndrome, linked to substance use, involves cognitive and emotional changes. Research suggests a connection to "hypofrontality," or reduced frontal lobe brain activity.
Area of Science:
- Neuroscience
- Psychiatry
- Addiction Medicine
Context:
- Amotivational syndrome is a chronic psychiatric condition.
- Historically linked to long-term cannabis use.
- Also observed with other psychoactive substances like solvents and methamphetamine.
Purpose:
- To explore the biological underpinnings of amotivational syndrome.
- To investigate the association between substance use and neurobiological changes.
- To understand the potential role of "hypofrontality" in the disorder.
Summary:
- Characterized by decreased activity, apathy, and cognitive deficits.
- Neuroimaging studies (MRI, SPECT) reveal white matter changes and frontal cortex hypoperfusion.
- Findings suggest a link to impaired frontal lobe function and "hypofrontality".
Impact:
- Highlights the neurobiological basis of substance-induced psychiatric conditions.
- Informs potential therapeutic targets for amotivational syndrome.
- Emphasizes the importance of considering frontal lobe function in treatment strategies.